A Phase 3 interventional study of CD5789 (trifarotene) 50µg/g Cream and Placebo Cream in Acne Vulgaris, sponsored by Galderma R&D. Completed at 81 sites in 8 countries. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2019-11-12.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing trifarotene in Acne Vulgaris — none open to participants now, 1 under way, 1 of them phase 3. trifarotene · Acne Vulgaris.
Among the 12 studies testing trifarotene in Acne Vulgaris, this one has the largest enrollment, is one of 3 that started in 2015, is one of 6 in phase 3, and was the 3rd registered.
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →None of the 12 studies testing trifarotene in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →
trifarotene: first FDA approval 2019 (AKLIEF). What it is approved for, and how studies give it, is on its page →
Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 9 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2015.
This study's enrollment of 1,212 is above the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 507 across the 12 interventional studies. Of the 11 that completed or were terminated, 9 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 3 most frequent:
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
49 studies in Acne Vulgaris by Galderma Group AG: none open now, 1 under way, 1 of them phase 3. Of 48 finished, 39 (81%) have results posted.
Among the 49 studies in Acne Vulgaris by Galderma Group AG, this one is the 3rd largest by enrollment of the 46 interventional ones that give a count, is one of 5 that started in 2015, is one of 20 in phase 3, and was the 37th registered.
Galderma Group AG’s Acne Vulgaris studies by the year they started, since 2004.
1 of the studies testing trifarotene in Acne Vulgaris that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07186413Phase 3Galderma R&DA Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing trifarotene in Acne Vulgaris, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Galderma Group AG’s 49 in Acne Vulgaris:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Assessment of the efficacy and safety of CD5789 (Trifarotene) 50µg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD5789 (trifarotene) 50µg/g Cream
Drug: CD5789 (trifarotene) 50µg/g Cream
Placebo Cream
Drug: Placebo Cream
Drug page: Trifarotene
CD5789 (Trifarotene) 50µg/g cream applied once daily during 12 weeks.
Placebo cream applied once daily during 12 weeks.
Investigator Global Assessment (IGA) Score of 1 (Almost Clear) or 0 (Clear)
Number of subjects who achieved an Investigator Global Assessment (IGA) score of 1 (almost clear) or 0 (Clear) and at least a 2-grade improvement from Baseline to Week 12.
Time frame: From Baseline to Week 12
| Milestone | CD5789 (Trifarotene) 50µg/g Cream | Placebo Cream |
|---|---|---|
| Started | 602 | 610 |
| Completed | 558 | 573 |
| Not completed | 44 | 37 |
Number of subjects who achieved an Investigator Global Assessment (IGA) score of 1 (almost clear) or 0 (Clear) and at least a 2-grade improvement from Baseline to Week 12.
| Participants | CD5789 (Trifarotene) 50µg/g Cream | Placebo Cream |
|---|---|---|
| Investigator Global Assessment (IGA) Score of 1 (Almost Clear) or 0 (Clear) | 255 | 157 |
Collected over Each participant's adverse events were collected starting at the first visit (screening) until the last visit (Week 12).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CD5789 (Trifarotene) 50µg/g Cream | 0/602 (0%) | 2/602 (0.3%) | 21/602 (3.5%) |
| Placebo Cream | 0/610 (0%) | 4/610 (0.7%) | 5/610 (0.8%) |
| Event | CD5789 (Trifarotene) 50µg/g Cream | Placebo Cream |
|---|---|---|
| Ligament SprainInjury, poisoning and procedural complications | 1/602 | 0/610 |
| Suicide AttemptPsychiatric disorders | 1/602 | 1/610 |
| Major DepressionPsychiatric disorders | 1/602 | 0/610 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/602 | 1/610 |
| AppendicitisInfections and infestations | 0/602 | 1/610 |
| SinusitisInfections and infestations | 0/602 | 1/610 |
| Event | CD5789 (Trifarotene) 50µg/g Cream | Placebo Cream |
|---|---|---|
| Application Site IrritationGeneral disorders | 15/602 | 0/610 |
| Application Site PuritisGeneral disorders | 5/602 | 2/610 |
| Application Site PainGeneral disorders | 4/602 | 0/610 |
| Application Site DrynessGeneral disorders | 3/602 | 0/610 |
| SunburnInjury, poisoning and procedural complications | 2/602 | 0/610 |
| Skin IrritationSkin and subcutaneous tissue disorders | 2/602 | 0/610 |
| Drug Administered at Inappropriate SiteInjury, poisoning and procedural complications | 1/602 | 0/610 |
| LymphadenopathyBlood and lymphatic system disorders | 1/602 | 0/610 |
| Eyelid ExfoliationEye disorders | 1/602 | 0/610 |
| Eyelid EdemaEye disorders | 1/602 | 0/610 |
| Age, Categorical(Participants) | CD5789 (Trifarotene) 50µg/g Cream | Placebo Cream | Total |
|---|---|---|---|
| <=18 years | 276 | 294 | 570 |
| Between 18 and 65 years | 326 | 316 | 642 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | CD5789 (Trifarotene) 50µg/g Cream | Placebo Cream | Total |
|---|---|---|---|
| Female | 357 | 338 | 695 |
| Male | 245 | 272 | 517 |
| Ethnicity (NIH/OMB)(Participants) | CD5789 (Trifarotene) 50µg/g Cream | Placebo Cream | Total |
|---|---|---|---|
| Hispanic or Latino | 60 | 62 | 122 |
| Not Hispanic or Latino | 542 | 548 | 1090 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | CD5789 (Trifarotene) 50µg/g Cream | Placebo Cream | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 2 | 3 |
| Asian | 2 | 6 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 27 | 42 | 69 |
| White | 565 | 554 | 1119 |
| More than one race | 2 | 2 | 4 |
| Unknown or Not Reported | 5 | 3 | 8 |
| Region of Enrollment(Participants) | CD5789 (Trifarotene) 50µg/g Cream | Placebo Cream | Total |
|---|---|---|---|
| Romania | 64 | 65 | 129 |
| Hungary | 74 | 66 | 140 |
| United States | 124 | 154 | 278 |
| Czechia | 63 | 60 | 123 |
| Ukraine | 71 | 74 | 145 |
| Poland | 92 | 96 | 188 |
| Russia | 100 | 81 | 181 |
| Spain | 14 | 14 | 28 |
| Investigator Global Asssessment(participants) | CD5789 (Trifarotene) 50µg/g Cream | Placebo Cream | Total |
|---|---|---|---|
| Clear | 0 | 0 | 0 |
| Almost Clear | 0 | 0 | 0 |
| Mild | 0 | 0 | 0 |
| Moderate | 602 | 610 | 1212 |
| Severe | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Nov 2015, a primary completion of Feb 2017 and a completion of May 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2019, 2 years 6 months after primary completion. A results delay was requested in May 2018.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trifarotene